These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 32466169

  • 1. The Synergistic Anti-Cancer Effects of NVP-BEZ235 and Regorafenib in Hepatocellular Carcinoma.
    Yu CC, Huang SY, Chang SF, Liao KF, Chiu SC.
    Molecules; 2020 May 25; 25(10):. PubMed ID: 32466169
    [Abstract] [Full Text] [Related]

  • 2. [β-Lapachone combined with NVP-BEZ235 inhibit proliferation and migration of BGC-823 gastric cancer cells].
    Cui X, Chen L, Sun J, Wang Y, Lin Z.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2018 Feb 25; 34(2):129-135. PubMed ID: 29673455
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
    Li H, Jin X, Zhang Z, Xing Y, Kong X.
    Cell Biochem Funct; 2013 Jul 25; 31(5):427-33. PubMed ID: 23086777
    [Abstract] [Full Text] [Related]

  • 4. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, Chen Y, Li Y, Zhao G.
    Cancer Lett; 2015 Oct 10; 367(1):58-68. PubMed ID: 26188279
    [Abstract] [Full Text] [Related]

  • 5. NVP-BEZ235 Attenuated Cell Proliferation and Migration in the Squamous Cell Carcinoma of Oral Cavities and p70S6K Inhibition Mimics its Effect.
    Hsu CM, Lin PM, Lin HC, Tsai YT, Tsai MS, Li SH, Wu CY, Yang YH, Lin SF, Yang MY.
    Int J Mol Sci; 2018 Nov 10; 19(11):. PubMed ID: 30423811
    [Abstract] [Full Text] [Related]

  • 6. Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-κB and VEGF/VEGFR2 signaling pathways.
    El-Hanboshy SM, Helmy MW, Abd-Alhaseeb MM.
    Mol Biol Rep; 2021 Nov 10; 48(11):7233-7242. PubMed ID: 34596810
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
    Ji Y, Di W, Yang Q, Lu Z, Cai W, Wu J.
    Clin Lab; 2015 Nov 10; 61(8):1043-51. PubMed ID: 26427150
    [Abstract] [Full Text] [Related]

  • 8. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
    Shoji K, Oda K, Kashiyama T, Ikeda Y, Nakagawa S, Sone K, Miyamoto Y, Hiraike H, Tanikawa M, Miyasaka A, Koso T, Matsumoto Y, Wada-Hiraike O, Kawana K, Kuramoto H, McCormick F, Aburatani H, Yano T, Kozuma S, Taketani Y.
    PLoS One; 2012 Nov 10; 7(5):e37431. PubMed ID: 22662154
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
    Deng J, Bai X, Feng X, Ni J, Beretov J, Graham P, Li Y.
    BMC Cancer; 2019 Jun 24; 19(1):618. PubMed ID: 31234823
    [Abstract] [Full Text] [Related]

  • 10. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.
    Santiskulvong C, Konecny GE, Fekete M, Chen KY, Karam A, Mulholland D, Eng C, Wu H, Song M, Dorigo O.
    Clin Cancer Res; 2011 Apr 15; 17(8):2373-84. PubMed ID: 21372221
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
    Xin P, Li C, Zheng Y, Peng Q, Xiao H, Huang Y, Zhu X.
    Drug Des Devel Ther; 2017 Apr 15; 11():1115-1126. PubMed ID: 28435223
    [Abstract] [Full Text] [Related]

  • 12. Suppressive effects of microRNA-16 on the proliferation, invasion and metastasis of hepatocellular carcinoma cells.
    Wu WL, Wang WY, Yao WQ, Li GD.
    Int J Mol Med; 2015 Dec 15; 36(6):1713-9. PubMed ID: 26499886
    [Abstract] [Full Text] [Related]

  • 13. Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy.
    Chang Z, Shi G, Jin J, Guo H, Guo X, Luo F, Song Y, Jia X.
    Int J Mol Med; 2013 Jun 15; 31(6):1449-56. PubMed ID: 23588698
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The PI3K/mTOR dual inhibitor NVP-BEZ235 stimulates mutant p53 degradation to exert anti-tumor effects on triple-negative breast cancer cells.
    Cai J, Xia J, Zou J, Wang Q, Ma Q, Sun R, Liao H, Xu L, Wang D, Guo X.
    FEBS Open Bio; 2020 Apr 15; 10(4):535-545. PubMed ID: 32027103
    [Abstract] [Full Text] [Related]

  • 17. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A, Li H, Li R, Lu L, Wu X.
    Oncol Rep; 2018 Oct 15; 40(4):2353-2362. PubMed ID: 30066933
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of sonic hedgehog and PI3K/Akt/mTOR pathways cooperate in suppressing survival, self-renewal and tumorigenic potential of glioblastoma-initiating cells.
    Nanta R, Shrivastava A, Sharma J, Shankar S, Srivastava RK.
    Mol Cell Biochem; 2019 Apr 15; 454(1-2):11-23. PubMed ID: 30251117
    [Abstract] [Full Text] [Related]

  • 19. Moscatilin Inhibits Metastatic Behavior of Human Hepatocellular Carcinoma Cells: A Crucial Role of uPA Suppression via Akt/NF-κB-Dependent Pathway.
    Yu CL, Weng MS, Chen WC, Chien KT, Chi CW, Chung CH, Huang CW, Wang PC, Chen CC, Tsai AC, Liu SC, Wang SW.
    Int J Mol Sci; 2021 Mar 13; 22(6):. PubMed ID: 33805784
    [Abstract] [Full Text] [Related]

  • 20. Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin.
    Ou DL, Lee BS, Lin LI, Liou JY, Liao SC, Hsu C, Cheng AL.
    Mol Cancer; 2014 Jan 03; 13():2. PubMed ID: 24387108
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.